These FGF21‐class molecules have been reported to have similar therapeutic efficacy than the native FGF21 protein in small and large animal models of obesity and T2D (Foltz et al, 2012; Hecht et al, 2012; Adams et al, 2013; Talukdar et al, 2016; Stanislaus et al, 2017). This evidence concerns the gene FGF21 and type 2 diabetes mellitus.